Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee...

Related Keywords

San Diego ,California ,United States ,Eli Lilly ,Bristol Myers Squibb ,Samantha Gaspar ,Linkedin ,Idorsia Pharmaceuticals ,Halozyme Therapeutics Inc ,Twitter ,Exchange Commission ,Corporate Communications ,Prnewswire Halozyme Therapeutics Inc ,Pfizer ,Nasdaq ,Drug Administration ,Acumen Pharmaceuticals ,Teva Pharmaceuticals ,Updated Prescription Drug User Fee Act ,Prescription Drug User Fee Act ,Biologics License Application ,Viiv Healthcare ,Chugai Pharmaceutical ,Quarterly Reports ,Investor Relations ,